Breast Cancer
A Look Back at 2022 FDA Approvals in Oncology
January 02, 2023
Podcast
In this episode of The Vitals, we recount the oncology drugs that received FDA approvals in 2022.
Black Women With HR+ Breast Cancer Experience Inferior Outcomes, Despite Comparable Recurrence Scores
January 01, 2023
Article
Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.
Real-World Data Show Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rates in HER2+ Breast Cancer
December 28, 2022
Article
Neoadjuvant pertuzumab/trastuzumab increased the rate of pathological complete response in patients with HER2-positive breast cancer.
Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast Cancer
December 26, 2022
Video
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.
Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast Cancer
December 26, 2022
Article
Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Camizestrant Emerges As A Potentially Effective Oral SERD for Patients With HER2-Negative Advanced Breast Cancer
December 24, 2022
Article
Camizestrant doubled progression-free survival compared with fulvestrant in patients with estrogen receptor–positive, HER2-negative advanced breast cancer.
Adjuvant T-DM1 With Concurrent Radiotherapy Is Not Associated with Cardiotoxic Concerns in Early-Stage HER2+ Breast Cancer
December 23, 2022
Article
Patients with early-stage, HER2-positive breast cancer who received both adjuvant ado-trastuzumab emtansine and concurrent radiotherapy did not experience a significant drop in ejection fraction or global longitudinal strain.
Label Update for Capecitabine Expands and Updates Indications
December 22, 2022
Article
The FDA has approved updated labeling for capecitabine under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for certain older oncology drugs.
Capivasertib/Fulvestrant Boosts Progression-Free Survival in HR+/HER2– Breast Cancer
December 21, 2022
Article
Capivasertib plus fulvestrant improved progression-free survival in patients who have hormone-receptor–positive/HER2-negative advanced breast cancer.
ASCO/SIO Panel Recommends Acupuncture For Adults With Aromatase Inhibitor–Related Joint Pain
December 21, 2022
Article
An ASCO/SIO expert panel outlined evidence supporting integrative therapies for adults. There is insufficient evidence in the pediatric population.